TCGA-55-7907-01A-11R-2170-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.310
- KRAS_SIGNALING_UP+0.280
- COMPLEMENT+0.270
- COAGULATION+0.230
- INFLAMMATORY_RESPONSE+0.220
- KRAS_SIGNALING_DN+0.210
- APICAL_JUNCTION+0.160
- IL6_JAK_STAT3_SIGNALING+0.150
- PEROXISOME+0.140
- ANGIOGENESIS+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- MYC_TARGETS_V1-0.490
- E2F_TARGETS-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.450
- G2M_CHECKPOINT-0.410
- OXIDATIVE_PHOSPHORYLATION-0.370
- DNA_REPAIR-0.360
- MTORC1_SIGNALING-0.360
- P53_PATHWAY-0.330
- PI3K_AKT_MTOR_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG47 | — | — | 0.876 |
| 2 | TCGA-CR-7391-01A-11R-2016-07 | — | — | 0.875 |
| 3 | C3L-03268 | — | cohortA1 | 0.874 |
| 4 | TCGA-D6-6824-01A-11R-1915-07 | — | — | 0.856 |
| 5 | TCGA-K4-A3WU-01B-11R-A23N-07 | — | — | 0.851 |
| 6 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.849 |
| 7 | TCGA-44-2659-01A-01R-0946-07 | — | cohortA1 | 0.848 |
| 8 | TCGA-86-8668-01A-11R-2403-07 | — | cohortA1 | 0.845 |
| 9 | TCGA-AC-A2FF-01A-11R-A17B-07 | — | A | 0.841 |
| 10 | TCGA-55-7724-01A-11R-2170-07 | — | cohortMD2 | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |